446 related articles for article (PubMed ID: 29239973)
1. Involvement of adenosine triphosphate-sensitive potassium channels in the neuroprotective activity of hydrogen sulfide in the 6-hydroxydopamine-induced animal model of Parkinson's disease.
Sarookhani MR; Haghdoost-Yazdi H; Sarbazi-Golezari A; Babayan-Tazehkand A; Rastgoo N
Behav Pharmacol; 2018 Jun; 29(4):336-343. PubMed ID: 29239973
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
3. Hydrogen sulfide attenuates induction and prevents progress of the 6-hydroxydopamine-induced Parkinsonism in rat through activation of ATP-sensitive potassium channels and suppression of ER stress.
Minaei A; Sarookhani MR; Haghdoost-Yazdi H; Rajaei F
Toxicol Appl Pharmacol; 2021 Jul; 423():115558. PubMed ID: 33961902
[TBL] [Abstract][Full Text] [Related]
4. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats.
Yin WL; Yin WG; Huang BS; Wu LX
Neurosci Lett; 2017 Sep; 657():45-52. PubMed ID: 28764908
[TBL] [Abstract][Full Text] [Related]
7. Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model.
Sarukhani MR; Haghdoost-Yazdi H; Khandan-Chelarci G
Neurochem Res; 2018 May; 43(5):1086-1095. PubMed ID: 29616443
[TBL] [Abstract][Full Text] [Related]
8. The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling.
Baluchnejadmojarad T; Eftekhari SM; Jamali-Raeufy N; Haghani S; Zeinali H; Roghani M
Exp Gerontol; 2017 Dec; 100():70-76. PubMed ID: 29107062
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
10. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen sulphide attenuates neuronal apoptosis of substantia nigra by re-establishing autophagic flux via promoting leptin signalling in a 6-hydroxydopamine rat model of Parkinson's disease.
Jiang W; Zou W; Hu M; Tian Q; Xiao F; Li M; Zhang P; Chen YJ; Jiang JM
Clin Exp Pharmacol Physiol; 2022 Jan; 49(1):122-133. PubMed ID: 34494284
[TBL] [Abstract][Full Text] [Related]
12. Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERβ/Nrf2/HO-1 signaling.
Baluchnejadmojarad T; Rabiee N; Zabihnejad S; Roghani M
Brain Res; 2017 May; 1662():23-30. PubMed ID: 28238669
[TBL] [Abstract][Full Text] [Related]
13. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
14. Leptin mediates protection of hydrogen sulfide against 6-hydroxydopamine-induced Parkinson's disease: Involving enhancement in Warburg effect.
Yang SQ; Tian Q; Li D; He SQ; Hu M; Liu SY; Zou W; Chen YJ; Zhang P; Tang XQ
Neurochem Int; 2020 May; 135():104692. PubMed ID: 32032636
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a 6-OHDA Induced Unilaterally Lesioned Male Wistar Rat Model of Parkinson's Disease.
Kumari N; Luthra PM
Methods Mol Biol; 2024; 2761():491-498. PubMed ID: 38427257
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
Jin F; Wu Q; Lu YF; Gong QH; Shi JS
Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of hydrogen sulfide in a rat model of traumatic brain injury via activation of mitochondrial adenosine triphosphate-sensitive potassium channels and reduction of oxidative stress.
Jiang X; Huang Y; Lin W; Gao D; Fei Z
J Surg Res; 2013 Oct; 184(2):e27-35. PubMed ID: 23590867
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease.
Ferro MM; Angelucci ME; Anselmo-Franci JA; Canteras NS; Da Cunha C
Braz J Med Biol Res; 2007 Jan; 40(1):89-96. PubMed ID: 17225001
[TBL] [Abstract][Full Text] [Related]
20. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
